Jazz Pharmaceuticals (JAZZ) Operating Margin (2010 - 2026)

Jazz Pharmaceuticals' Operating Margin history runs 17 years deep, the most recent figure standing at 31.49% for Q1 2026.

• In Q1 2026, Operating Margin rose 3772.0% year-over-year to 31.49%; the TTM figure through Mar 2026 stood at 0.85% (down 1548.0% YoY), while the FY2025 annual figure was 10.08%, down 2769.0% from the prior year.
• Operating Margin for Q1 2026 stood at 31.49%, up from 21.25% in the prior quarter.
• The five-year high for Operating Margin was 31.49% in Q1 2026, with the low at 65.64% in Q2 2025.
• The 5-year median for Operating Margin is 12.11% (2023), against an average of 6.52%.
• The sharpest annual moves came in 2023 and 2025: Operating Margin soared 3920 bps in 2023, then plunged 8512 bps in 2025.
• Jazz Pharmaceuticals' Operating Margin stood at 27.09% in 2022, then jumped by 145 bps to 12.11% in 2023, then jumped by 45 bps to 17.53% in 2024, then grew by 21 bps to 21.25% in 2025, then jumped by 48 bps to 31.49% in 2026.
• Business Quant data shows JAZZ's Operating Margin at 31.49% in Q1 2026, 21.25% in Q4 2025, and 5.11% in Q3 2025.